Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cardiovascular/Coronary Microvascular Dysfunction

Coronary Microvascular Dysfunction

1

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Coronary Microvascular Dysfunction is an early-stage landscape with 1 program across 3 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

25/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 1

No programs

Phase 2

No programs

Phase 31

Diltiazem Hydrochloride

University of South Florida

Approved

No programs

Analysis

Trial Status

8

clinical trials

Active, not recruiting3 · 38%

Withdrawn1 · 13%

Terminated1 · 13%

Unknown status1 · 13%

Not yet recruiting1 · 13%

Recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Women's Ischemia Syndrome Evaluation (WISE) Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting·CCedars-Sinai Medical Center·N/A·NCT03876223·180 enrolled

Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial

Active, not recruiting·RRadboud University Medical Center·Phase 3·NCT04777045·85 enrolled

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

Active, not recruiting·NNYU Langone Health·N/A·NCT03537586·206 enrolled

Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)

Active, not recruiting·VVahatiCor, Inc.·Preclinical·NCT06991322·30 enrolled

A Plant-Based Diet in the Treatment of Coronary Microvascular Dysfunction (CMD)

Not yet recruiting·EEmory University·Preclinical·NCT07821372·20 enrolled

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Terminated·LLisata Therapeutics, Inc.·Phase 2·NCT04614467·34 enrolled

Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine

Withdrawn·TThomas Jefferson University·Phase 1·NCT03184155

Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction

Unknown status·SShanghai Hutchison Pharmaceuticals Limited·Phase 4·NCT04984954·264 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)